Prospective Study of Human Papillomavirus Seropositivity and Risk of Nonmelanoma Skin Cancer

Abstract

Cutaneous human papillomaviruses (HPVs) have been associated with squamous cell carcinoma (SCC) in case-control studies, but there are limited data from prospective studies assessing whether virus exposure predicts risk of future cancer development. Two major biobanks, the Southern Sweden Microbiology Biobank (1971-2003) and the Janus Biobank (1973-2003) in Norway, containing samples from 850,000 donors, were searched for incident skin cancer for up to 30 years using registry linkages. Altogether, 2,623 donors with samples taken before diagnosis of SCC or basal cell carcinoma (BCC) of the skin were identified. Prediagnostic samples and samples from 2,623 matched controls were tested for antibodies against 33 types of HPV. Baseline seropositivity to HPV types in genus β species 2 was associated with SCC risk (odds ratio = 1.3, 95% confidence interval: 1.1, 1.7); this was also the case for samples taken more than 18 years before diagnosis (odds ratio = 1.8, 95% confidence interval: 1.1, 2.8). Type-specific persistent seropositivity entailed elevated point estimates for SCC risk for 29 HPV types and decreased point estimates for only 3 types. After multiple hypothesis adjustment, HPV 76 was significantly associated with SCC risk and HPV 9 with BCC risk. In summary, seropositivity for certain HPV types was associated with an increased risk for future development of SCC and BCC.

Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: A multicenter, prospective cohort study

“…Case‐control studies in both OTR and immunocompetent populations have shown that the presence of βPV DNA or antibodies was associated with a 1.5‐ to 3‐fold increased risk of cSCC 12, 20, 21, 22, 23, 24, 25, 26, 29, 31, 32. It was not possible, however, to determine whether the βPV infection increases risk of cSCC development or whether cSCC formation promotes active proliferation of βPV.…”

Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Case–Control Study

“…Previously, we reported weak associations between HPV types 3, 15, 38, and 76 and future risk of SCC (3). The previous study was carried out using an HPV serologic method (GST-L1 fusion proteins) that has only weak association with HPV infection (4).…”

“…The samples from cases and matched controls were tested for IgG to pseudovirions to 16 different HPV types (3,5,6, 11, 15, 16, 18, 31, 32, 33, 38, 45, 52, 58, 68, and 76) and two polyomaviruses (MCPyV and JCPyV).…”

Human papilloma virus infection in basal cell carcinoma of the skin: a systematic review and meta-analysis study

“…Out of 45 studies reported during 1991 to 2017; two studies were reported in Australia [12,13], one Romania [14], ten USA [15,16,17,18,19,20,21,22,23,24], one Argentina [1], four Netherlands [25,26,27,28], two Spain [8,11], one Brazil [29], one China [30], one UK [31], one Croatia [2], four Iran [9,32,33,34], one North Africa/France [35], one Germany/USA [36], two Greece [37,38], one Sweden/Austria [39], two Germany [40,41], five Italy [5,42,43,44,45], one Russia [46], one Germany/Poland [47], one Norway/Sweden [48] and two Sweden [49,50] (Table I). Fifteen studies were case-control and 30 studies were cross-sectional studies.…”